Omicron

In COVID-19 clinical update #101, Daniel Griffin discusses children and COVID, human challenge study results, effectiveness of mask use, Omicron boost in macaques, mucosal vaccine candidate, long-term cardiovascular outcomes, and global vaccine perceptions.

In COVID-19 clinical update #100, Daniel Griffin, from Accra, Ghana, reviews the challenges in evaluating Omicron severity, over 800 deaths in children, Pfizer vaccine EUA application for under 5 year olds, false positives from soft drinks, Novavax vaccine EUA application, childhood experiences and vaccine hesitancy, fourth vaccine dose in Israel, effects of antivirals and monoclonals against Omicron, and multiple factors associated with PASC.

Nels joins TWiV to discuss hypotheses for the origins of Omicron, including that it came from mice or arose during chronic infection of an immunocompromised patient.

Jon Yewdell returns to TWiV to discuss how antibodies are made, vaccination against SARS-CoV-2, antigenic variation of the virus, booster shots, and more.

In COVID-19 clinical update #98, Daniel Griffin reviews COVID-19 in South Africa, recognition of Omicron by ancestral T cells, booster effectiveness against disease, infection and vaccination in pregnant women, early Remdesivir to prevent progression to severe disease, management of hospitalized adults, Tocilizumab in hospitalized patients, vaccination and long COVID, and the true toll of the pandemic.

In COVID-19 clinical update #97, Daniel Griffin covers immunity after infection recognized by CDC, outcomes before and after Omicron, infectious viral load in Delta vs Omicron, PCR vs rapid antigen tests, booster interval shortened to 5 months, risk factors for severe outcomes in vaccinated, cross-reactive memory T cells, vaccine effectiveness vs MIS-C, and Rivaroxiban for thromboprophylaxis.

In COVID-19 clinical update #96, Daniel Griffin reviews Omicron in South Africa, rapid antigen tests, viral coinfections, isolation and quarantine, saliva preferred for Omicron, risk factors for severe disease in vaccinated, Paxlovid dosing, and long COVID.

In COVID-19 clinical update #95, Daniel Griffin discusses new CDC guidelines for isolation and quarantine, EUA for Molnupiravir, children and COVID, vaccine safety in 5-11 year olds, Omicron outbreaks in Nebraska and Denmark, Baylor’s COVID vaccine, and COVID-OUT for ivermectin.

In COVID-19 clinical update #94, Daniel Griffin reviews the FDA EUA for Paxlovid, test to stay in school, immunity after infection, variants and therapeutics, quarantine and isolation guidelines, Molnupiravir in non-hospitalized patients, and convalescent serum in outpatients.